Spero Therapeutics, Inc.
SPROFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Spero Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Spero Therapeutics, Inc. — 10-K filed Mar 26, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 11 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 25, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| STATE STREET CORP | 2026-03-31 | 214,751 | $503K | SEC filing |
| INTREPID FAMILY OFFICE LLC | 2026-03-31 | 16,279 | $38.1K | SEC filing |
| Anson Funds Management LP | 2026-03-31 | 421,956 | $987K | SEC filing |
| Invesco Ltd. | 2026-03-31 | 45,374 | $106K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 519,922 | $1.22M | SEC filing |
| Schonfeld Strategic Advisors LLC | 2026-03-31 | 20,314 | $47.5K | SEC filing |
| OCCUDO QUANTITATIVE STRATEGIES LP | 2026-03-31 | 16,421 | $41.2K | SEC filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2026-03-31 | 28,565 | $66.8K | SEC filing |
| Farther Finance Advisors, LLC | 2026-03-31 | 10 | $25 | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2026-03-31 | 1,189,235 | $2.78M | SEC filing |
| Shay Capital LLC | 2026-03-31 | 70,354 | $165K | SEC filing |
| GSK plc | 2026-03-31 | 9,190,606 | $21.5M | SEC filing |
| Pfizer Inc | 2026-03-31 | 2,362,348 | $5.5M | SEC filing |
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 200 | $468 | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 236 | $529 | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 376,458 | $881K | SEC filing |
| Torrey Growth & Income Advisors | 2026-03-31 | 17,025 | $37.6K | SEC filing |
| Squarepoint Ops LLC | 2026-03-31 | 194,301 | $455K | SEC filing |
| MARSHALL WACE, LLP | 2026-03-31 | 157,072 | $368K | SEC filing |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 2026-03-31 | 114,800 | $269K | SEC filing |
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- CITIGROUP INC: 17 shares reported 2025-12-31; 19,135 shares reported 2026-03-31.
- SBI Securities Co., Ltd.: 9 shares reported 2025-12-31; 9 shares reported 2026-03-31.
- Assenagon Asset Management S.A.: 18,636 shares reported 2025-12-31; 18,636 shares reported 2026-03-31.
- BlackRock, Inc.: 433,616 shares reported 2025-12-31; 433,202 shares reported 2026-03-31.
- FNY Investment Advisers, LLC: 5,300 shares reported 2025-12-31; 5,300 shares reported 2026-03-31.
- TWO SIGMA INVESTMENTS, LP: 372,570 shares reported 2025-12-31; 885,631 shares reported 2026-03-31.
- Capital Asset Advisory Services LLC: 32,548 shares reported 2025-12-31; 32,548 shares reported 2026-03-31.
- SUSQUEHANNA INTERNATIONAL GROUP, LLP: 293,700 shares reported 2025-12-31; 333,115 shares reported 2026-03-31.
- Alphabet Inc.: 889,979 shares reported 2025-12-31; 889,979 shares reported 2026-03-31.
- US BANCORP \DE\: 151 shares reported 2025-12-31; 151 shares reported 2026-03-31.
- GSA CAPITAL PARTNERS LLP: 178,930 shares reported 2025-12-31; 278,304 shares reported 2026-03-31.
- Ionic Capital Management LLC: 195,939 shares reported 2025-12-31; 195,939 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
20 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Spero Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-06 · Rajavelu Esther: Larger than 54 of the 57 other insider sales of Common Stock on file. SEC filing
- 2025-02-05 · Mahadevia Ankit: Larger than 55 of the 57 other insider sales of Common Stock on file. SEC filing
- 2025-02-05 · Shukla Sath: Larger than all 57 other insider sales of Common Stock on file. SEC filing
- 2025-02-05 · Shukla Sath: Larger than 52 of the 57 other insider sales of Common Stock on file. SEC filing
- 2024-02-05 · Shukla Sath: Larger than 53 of the 57 other insider sales of Common Stock on file. SEC filing
- 2024-02-02 · Mahadevia Ankit: Larger than 56 of the 57 other insider sales of Common Stock on file. SEC filing
- 2021-10-29 · Aquilo Capital, L.P.: Larger than 25 of the 26 other insider purchases of Common Stock, $0.001 par value on file. SEC filing
- 2021-08-23 · Aquilo Capital, L.P.: Larger than 24 of the 26 other insider purchases of Common Stock, $0.001 par value on file. SEC filing
- 2021-08-20 · Aquilo Capital, L.P.: Larger than all 26 other insider purchases of Common Stock, $0.001 par value on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-04 | Rajavelu Esther · See Remarks | Common Stock | S — Open market or private sale | −25,240 | 2.51 | SEC filing |
| 2026-02-06 | Keutzer Timothy · Chief Operating Officer | Common Stock | S — Open market or private sale | −18,652 | 2.36 | SEC filing |
| 2026-02-06 | Rajavelu Esther · See Remarks | Common Stock | S — Open market or private sale | −50,816 | 2.36 | SEC filing |
| 2026-02-06 | Rajavelu Esther · See Remarks | Common Stock | S — Open market or private sale | −37,101 | 2.36 | SEC filing |
| 2026-02-04 | Keutzer Timothy · Chief Operating Officer | Common Stock | S — Open market or private sale | −3,471 | 2.24 | SEC filing |
| 2026-02-03 | Keutzer Timothy · Chief Operating Officer | Common Stock | S — Open market or private sale | −24,224 | 2.14 | SEC filing |
| 2026-02-02 | Rajavelu Esther · See Remarks | Common Stock | S — Open market or private sale | −18,442 | 2.20 | SEC filing |
| 2026-02-02 | Keutzer Timothy · Chief Operating Officer | Common Stock | S — Open market or private sale | −18,891 | 2.20 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-23 | VINK PATRICK V.J.J. · Director | Common Stock | A — Grant, award, or other acquisition | +10,000 | SEC filing |
| 2026-06-23 | Pottage John C Jr · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-06-23 | THOMAS FRANK E · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-06-23 | Smith Cynthia · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-06-23 | THOMAS FRANK E · Director | Common Stock | A — Grant, award, or other acquisition | +10,000 | SEC filing |
| 2026-06-23 | Smith Cynthia · Director | Common Stock | A — Grant, award, or other acquisition | +10,000 | SEC filing |
| 2026-06-23 | Jackson Scott Thomas · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-06-23 | VINK PATRICK V.J.J. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.